MEM-288 Oncolytic Virus Trial
Phase 1
40
about 9.7 years
18+
2 sites in FL, NC
What this study is about
This trial is testing a new treatment, MEM-288, which is an oncolytic virus. It's being tested alone and in combination with standard cancer treatments like docetaxel and nivolumab to see if it can help people with advanced solid tumors.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive MEM-288 Intratumoral Injection
- 2.Receive Nivolumab
- 3.Take Docetaxel
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
docetaxel, nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells)
infusion, injection
Primary: Part 1A Monotherapy: Maximum Tolerated Dose (MTD), Safety and Tolerability assessed by Adverse Events (AEs)
Secondary: Disease Control Rate (DCR), Overall Response Rate (ORR), Overall Survival (OS), Progression Free Survival (PFS)
Oncology